<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018664</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 1008910 (TR08)</org_study_id>
    <nct_id>NCT04018664</nct_id>
  </id_info>
  <brief_title>Oral Abuse Potential Study of Nalbuphine</brief_title>
  <official_title>A Study to Evaluate the Oral Abuse Potential of Nalbuphine Solution and Extended-Release Intact Tablets in Non-Dependent, Recreational Opioid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trevi Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the effects of a drug called nalbuphine (an opioid&#xD;
      drug) compared with the effects of hydromorphone (an opioid drug) and placebo (contains no&#xD;
      active drug ingredients). The amount of nalbuphine levels in the blood will also be measured&#xD;
      and the safety of the study drugs will be evaluated.&#xD;
&#xD;
      This study has 2 parts: Part A and Part B.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a single-dose, randomized, double-blind, active- and placebo-controlled,&#xD;
      double dummy, 2-part, 7-way crossover study to determine the abuse potential of orally&#xD;
      administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone&#xD;
      solution and placebo, in non-dependent, recreational opioid users. The study will be&#xD;
      conducted in a single clinical research unit (CRU).&#xD;
&#xD;
      The purpose of Part A is to find the appropriate doses (a low, intermediate, and high dose)&#xD;
      of nalbuphine solution to use in Part B. Part A of the study has two visits to the research&#xD;
      clinic: a screening visit and dose selection visit. The visits will involve a 2-night stay (3&#xD;
      days total) in the research clinic.&#xD;
&#xD;
      In the Main Study Treatment Phase in Part B, the total estimated duration between each dose&#xD;
      of study drug is approximately up to 7 days, of which the subject will spend 3 days/2 nights&#xD;
      in the research clinic and approximately up to 4 days at home.&#xD;
&#xD;
      The primary objective of the Main Study is to evaluate the abuse potential of orally&#xD;
      administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone&#xD;
      solution (the active comparator) and placebo in non-dependent, recreational opioid users.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Actual">June 2, 2020</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-dose, randomized, double-blind, active- and placebo-controlled, double-dummy, 2-part, 7-way crossover study.&#xD;
Part A: Dose selection phase Part B: Treatment Periods 1-7</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>For each dosing cohort, an unblinded statistician, not otherwise involved in the study, will prepare a list of subject randomization numbers. These randomization numbers will be used to prepare individual subject doses. Sealed qualification code break envelopes will be available for each subject in case of emergency.&#xD;
Upon completion of each cohort of subjects, the randomization codes for the completed subjects will be unblinded by the CRU pharmacy. After unblinding, the safety data will be reviewed to determine if dosing can proceed for the next planned dosing cohort,</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).</measure>
    <time_frame>0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Only Part A of thie study was conducted because of closure the clinical research unit (CRU) before Part B could be initiated. Summary statistics are provided for C-max</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Nalbuphine</condition>
  <condition>Opioid Abuse</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo&#xD;
150 mL flavored beverage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg nalbuphine HCl solution&#xD;
9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg nalbuphine HCl solution&#xD;
12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg nalbuphine HCl solution&#xD;
15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 mg nalbuphine HCl solution&#xD;
18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>270 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>270 mg nalbuphine HCl solution&#xD;
27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Up to 405 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 405 mg nalbuphine HCl solution&#xD;
Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Up to 540 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 540 mg nalbuphine HCl solution&#xD;
Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine HCl solution</intervention_name>
    <description>nalbuphine solution administered at various strengths</description>
    <arm_group_label>120 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_label>150 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_label>180 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_label>270 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_label>90 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_label>Up to 405 mg nalbuphine HCl solution</arm_group_label>
    <arm_group_label>Up to 540 mg nalbuphine HCl solution</arm_group_label>
    <other_name>NAL ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects 18 to 55 years of age&#xD;
&#xD;
          -  Current opioid users who have used opioids for recreational (non-therapeutic) purposes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Self-reported substance or alcohol dependence (excluding nicotine and caffeine)&#xD;
&#xD;
          -  Heavy smoker (≥ 20 cigarettes per day) and/or who is unable to abstain from smoking&#xD;
             for at least 8 hours during the in clinic periods.&#xD;
&#xD;
          -  History or presence of clinically significant abnormality as assessed by physical&#xD;
             examination, medical history, ECGs, vital signs, or laboratory values.&#xD;
&#xD;
          -  History or presence of any clinically significant illness&#xD;
&#xD;
          -  History of major mental illness that may affect the ability of the subject to&#xD;
             participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Sciascia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trevi Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>001</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <results_first_submitted>August 8, 2020</results_first_submitted>
  <results_first_submitted_qc>August 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2020</results_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nalbuphine</keyword>
  <keyword>abuse potential</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalbuphine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT04018664/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT04018664/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only Part A of this study was completed. Treatment arms summarized are those that were used on in Part A.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo&#xD;
150 mL flavored beverage&#xD;
Placebo solution: Placebo</description>
        </group>
        <group group_id="P2">
          <title>90 mg Nalbuphine HCl Solution</title>
          <description>90 mg nalbuphine HCl solution&#xD;
9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="P3">
          <title>120 mg Nalbuphine HCl Solution</title>
          <description>120 mg nalbuphine HCl solution&#xD;
12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="P4">
          <title>150 mg Nalbuphine HCl Solution</title>
          <description>150 mg nalbuphine HCl solution&#xD;
15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="P5">
          <title>180 mg Nalbuphine HCl Solution</title>
          <description>180 mg nalbuphine HCl solution&#xD;
18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="P6">
          <title>270 mg Nalbuphine HCl Solution</title>
          <description>270 mg nalbuphine HCl solution&#xD;
27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="P7">
          <title>Up to 405 mg Nalbuphine HCl Solution</title>
          <description>Up to 405 mg nalbuphine HCl solution&#xD;
Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="P8">
          <title>Up to 540 mg Nalbuphine HCl Solution</title>
          <description>Up to 540 mg nalbuphine HCl solution&#xD;
Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo&#xD;
150 mL flavored beverage&#xD;
Placebo solution: Placebo</description>
        </group>
        <group group_id="B2">
          <title>90 mg Nalbuphine HCl Solution</title>
          <description>90 mg nalbuphine HCl solution&#xD;
9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="B3">
          <title>120 mg Nalbuphine HCl Solution</title>
          <description>120 mg nalbuphine HCl solution&#xD;
12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="B4">
          <title>150 mg Nalbuphine HCl Solution</title>
          <description>150 mg nalbuphine HCl solution&#xD;
15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="B5">
          <title>180 mg Nalbuphine HCl Solution</title>
          <description>180 mg nalbuphine HCl solution&#xD;
18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="B6">
          <title>270 mg Nalbuphine HCl Solution</title>
          <description>270 mg nalbuphine HCl solution&#xD;
27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="B7">
          <title>Up to 405 mg Nalbuphine HCl Solution</title>
          <description>Up to 405 mg nalbuphine HCl solution&#xD;
Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="B8">
          <title>Up to 540 mg Nalbuphine HCl Solution</title>
          <description>Up to 540 mg nalbuphine HCl solution&#xD;
Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="8.3"/>
                    <measurement group_id="B2" value="38.5" spread="11.2"/>
                    <measurement group_id="B3" value="33.2" spread="7.3"/>
                    <measurement group_id="B4" value="31.0" spread="9.4"/>
                    <measurement group_id="B5" value="37.3" spread="13.6"/>
                    <measurement group_id="B6" value="34.8" spread="5.6"/>
                    <measurement group_id="B7" value="34.3" spread="11.9"/>
                    <measurement group_id="B8" value="42.5" spread="12.3"/>
                    <measurement group_id="B9" value="35.3" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m**2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.48" spread="3.45"/>
                    <measurement group_id="B2" value="26.17" spread="3.15"/>
                    <measurement group_id="B3" value="25.53" spread="4.04"/>
                    <measurement group_id="B4" value="23.48" spread="2.57"/>
                    <measurement group_id="B5" value="26.18" spread="4.39"/>
                    <measurement group_id="B6" value="25.43" spread="3.62"/>
                    <measurement group_id="B7" value="24.53" spread="3.17"/>
                    <measurement group_id="B8" value="22.32" spread="1.55"/>
                    <measurement group_id="B9" value="25.23" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).</title>
        <description>Only Part A of thie study was conducted because of closure the clinical research unit (CRU) before Part B could be initiated. Summary statistics are provided for C-max</description>
        <time_frame>0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>C max</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo&#xD;
150 mL flavored beverage&#xD;
Placebo solution: Placebo</description>
          </group>
          <group group_id="O2">
            <title>90 mg Nalbuphine HCl Solution</title>
            <description>90 mg nalbuphine HCl solution&#xD;
9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
          </group>
          <group group_id="O3">
            <title>120 mg Nalbuphine HCl Solution</title>
            <description>120 mg nalbuphine HCl solution&#xD;
12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
          </group>
          <group group_id="O4">
            <title>150 mg Nalbuphine HCl Solution</title>
            <description>150 mg nalbuphine HCl solution&#xD;
15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
          </group>
          <group group_id="O5">
            <title>180 mg Nalbuphine HCl Solution</title>
            <description>180 mg nalbuphine HCl solution&#xD;
18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
          </group>
          <group group_id="O6">
            <title>270 mg Nalbuphine HCl Solution</title>
            <description>270 mg nalbuphine HCl solution&#xD;
27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
          </group>
          <group group_id="O7">
            <title>Up to 405 mg Nalbuphine HCl Solution</title>
            <description>Up to 405 mg nalbuphine HCl solution&#xD;
Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
          </group>
          <group group_id="O8">
            <title>Up to 540 mg Nalbuphine HCl Solution</title>
            <description>Up to 540 mg nalbuphine HCl solution&#xD;
Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
          </group>
        </group_list>
        <measure>
          <title>To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).</title>
          <description>Only Part A of thie study was conducted because of closure the clinical research unit (CRU) before Part B could be initiated. Summary statistics are provided for C-max</description>
          <population>C max</population>
          <units>microgram/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="21.70" spread="6.65"/>
                    <measurement group_id="O3" value="51.90" spread="26.89"/>
                    <measurement group_id="O4" value="68.67" spread="30.19"/>
                    <measurement group_id="O5" value="76.60" spread="51.34"/>
                    <measurement group_id="O6" value="56.00" spread="6.09"/>
                    <measurement group_id="O7" value="158.55" spread="115.65"/>
                    <measurement group_id="O8" value="196.83" spread="92.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo&#xD;
150 mL flavored beverage&#xD;
Placebo solution: Placebo</description>
        </group>
        <group group_id="E2">
          <title>90 mg Nalbuphine HCl Solution</title>
          <description>90 mg nalbuphine HCl solution&#xD;
9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="E3">
          <title>120 mg Nalbuphine HCl Solution</title>
          <description>120 mg nalbuphine HCl solution&#xD;
12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="E4">
          <title>150 mg Nalbuphine HCl Solution</title>
          <description>150 mg nalbuphine HCl solution&#xD;
15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="E5">
          <title>180 mg Nalbuphine HCl Solution</title>
          <description>180 mg nalbuphine HCl solution&#xD;
18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="E6">
          <title>270 mg Nalbuphine HCl Solution</title>
          <description>270 mg nalbuphine HCl solution&#xD;
27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="E7">
          <title>Up to 405 mg Nalbuphine HCl Solution</title>
          <description>Up to 405 mg nalbuphine HCl solution&#xD;
Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
        <group group_id="E8">
          <title>Up to 540 mg Nalbuphine HCl Solution</title>
          <description>Up to 540 mg nalbuphine HCl solution&#xD;
Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage&#xD;
Nalbuphine HCl solution: nalbuphine solution administered at various strengths</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Sciascia, MD</name_or_title>
      <organization>Trevi Therapeutics</organization>
      <phone>203-304-2499</phone>
      <email>thomas.sciascia@trevitherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

